For research use only. Not for therapeutic Use.
SDZ 220-581 Ammonium salt is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7[1].
SDZ 220-581 (3.2-32 mg/kg; oral administration; for 24 hours; male OF-l mice) treatment dose-dependently protects mice against maximal electroshock seizures (MES). The time-course of protection by SDZ 220-581 is characterized by a rapid onset and long duration of action[1].
| Catalog Number | I002325 |
| CAS Number | 179411-94-0 |
| Synonyms | (2S)-2-amino-3-[3-(2-chlorophenyl)-5-(phosphonomethyl)phenyl]propanoic acid;azane |
| Molecular Formula | C16H20ClN2O5P |
| Purity | ≥95% |
| InChI | InChI=1S/C16H17ClNO5P.H3N/c17-14-4-2-1-3-13(14)12-6-10(8-15(18)16(19)20)5-11(7-12)9-24(21,22)23;/h1-7,15H,8-9,18H2,(H,19,20)(H2,21,22,23);1H3/t15-;/m0./s1 |
| InChIKey | JSKZYMJZKPLCNJ-RSAXXLAASA-N |
| SMILES | C1=CC=C(C(=C1)C2=CC(=CC(=C2)CP(=O)(O)O)CC(C(=O)O)N)Cl.N |
| Reference | [1]. Urwyler S, et al. Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists–II. Pharmacological characterization in vivo. Neuropharmacology. 1996 Jun;35(6):655-69. [2]. Gilmour G, et al. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39. |
